Skip to content


Impavido (miltefosine) is a small molecule pharmaceutical. Miltefosine was first approved as Impavido on 2014-03-19. It is used to treat cutaneous leishmaniasis, leishmaniasis, and visceral leishmaniasis in the USA. It is known to target RAC-alpha serine/threonine-protein kinase.
Trade Name Impavido
Common Name Miltefosine
Indication cutaneous leishmaniasis, leishmaniasis, visceral leishmaniasis
Drug Class Phosphoro-derivatives
Get full access now